Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity
Prenitha Mercy Ignatius Arokia Doss,
Muhammad Umair,
Joanie Baillargeon,
Reda Fazazi,
Neva Fudge,
Irshad Akbar,
Asmita Pradeep Yeola,
John B. Williams,
Mickael Leclercq,
Charles Joly-Beauparlant,
Philippe Beauchemin,
Gian Filipo Ruda,
Melanie Alpaugh,
Ana C. Anderson,
Paul E. Brennan,
Arnaud Droit,
Hans Lassmann,
Craig S. Moore,
Manu Rangachari
Affiliations
Prenitha Mercy Ignatius Arokia Doss
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Muhammad Umair
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Joanie Baillargeon
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Reda Fazazi
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Neva Fudge
Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6, Canada
Irshad Akbar
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Asmita Pradeep Yeola
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
John B. Williams
Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6, Canada
Mickael Leclercq
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Charles Joly-Beauparlant
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Philippe Beauchemin
Department of Neurology, CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada; Faculty of Medicine, Université Laval, 1050 ave de la Médecine, Quebec City, QC, Canada
Gian Filipo Ruda
Target Discovery Institute and NIHR, Oxford Biomedical Research Centre, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK
Melanie Alpaugh
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada
Ana C. Anderson
Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham & Women’s Hospital, 60 Fenwood Road, Boston, MA 02115, USA
Paul E. Brennan
Target Discovery Institute and NIHR, Oxford Biomedical Research Centre, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK; Alzheimer’s Research UK, Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK
Arnaud Droit
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada; Faculty of Medicine, Université Laval, 1050 ave de la Médecine, Quebec City, QC, Canada
Hans Lassmann
Division of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, Vienna 1090, Austria
Craig S. Moore
Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6, Canada; Department of Neurology, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6, Canada
Manu Rangachari
axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Pavillon CHUL, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada; Faculty of Medicine, Université Laval, 1050 ave de la Médecine, Quebec City, QC, Canada; Corresponding author
Summary: Sex differences in multiple sclerosis (MS) incidence and severity have long been recognized. However, the underlying cellular and molecular mechanisms for why male sex is associated with more aggressive disease remain poorly defined. Using a T cell adoptive transfer model of chronic experimental autoimmune encephalomyelitis (EAE), we find that male Th17 cells induce disease of increased severity relative to female Th17 cells, irrespective of whether transferred to male or female recipients. Throughout the disease course, a greater frequency of male Th17 cells produce IFNγ, a hallmark of pathogenic Th17 responses. Intriguingly, XY chromosomal complement increases the pathogenicity of male Th17 cells. An X-linked immune regulator, Jarid1c, is downregulated in pathogenic male murine Th17 cells, and functional experiments reveal that it represses the severity of Th17-mediated EAE. Furthermore, Jarid1c expression is downregulated in CD4+ T cells from MS-affected individuals. Our data indicate that male sex chromosomal complement critically regulates Th17 cell pathogenicity.